Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting.

ABSTRACT: BackgroundPlasma p-tau217 shows exceptional diagnostic performance for Alzheimer's disease (AD) in cohort studies. Recent real-world studies support its validity in more diverse populations.ObjectiveTest the performance of plasma p-tau217 in representative real-world early-onset cognitive disorders patients.Methods118 adult patients with cognitive complaints or potential neurodegenerative diseases (ND) from a single healthcare network in Melbourne, Australia, were categorized into three groups based on clinical diagnosis: non-ND (n = 52), early-onset AD (EOAD, n = 39), and non-AD ND (other-ND, n = 27). Plasma p-tau217 was measured using the Simoa^® ALZpath p-Tau 217 Assay.ResultsPlasma p-tau217 was elevated in EOAD (mean ± SD: 1.13 ± 0.51) compared with non-ND (0.31 ± 0.27, p = 5

SUBMITTER: Chatterjee P 

PROVIDER: S-EPMC12541113 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature